Search our team at AdventHealth Research Institute
-
NCT05987241
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103
This study is currently enrolling.Associated Conditions: Bladder CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an...
-
NCT05645692
B044157 A Phase II, Randomized, Multicenter, Open-Label, Controlled Study Of R07247669 Alone Or In Combination With Tiragolumab Versus Atezolizumab In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Bladder Cancer Who Are Ineligible For Platinum-Containing Chemotherapy
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, Florida -
NCT05929235
A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Celebration, Florida -
Deep-learning of digital histopathology, radiomics and clinical factors to develop precision medicine with first-line gemcitabine-cisplatin-nivolumab for metastatic urothelial carcinoma: analysis of the CHECKMATE901 Phase III trial
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer Research -
A Nanotechnology-Enabled Blood Test for Cancer Detection and Diagnosis
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchThe purpose of this study is to determine if a new blood test can be used for early detection of prostate and kidney cancer. The results of this study may be published in a peer-reviewed scientific...
-
NCT06305767
A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
This study is currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaTo compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed... -
NCT04724018
DF/HCC 20-614 Combinations of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy (DAD-IO) Phase I/II trial
This study is not currently enrolling.Associated Conditions: Urothelial CancerResearch Area: Clinical Cancer Research -
E303-1001S: A Phase I/II, Open-label, Multi-center, First-in-human Trial to Investigate E303 in Participants with Unresectable or Metastatic Solid Tumors and Urothelial Carcinoma
This study is not currently enrolling.Research Area: Clinical Cancer Research -
NCT4579224
S1937, A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic)...